A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer

Medical Oncology
Kei SaitoKazuhiko Koike

Abstract

There has been a pressing need to develop optimal regimen for neoadjuvant chemotherapy (NAC) for pancreatic cancer (PC). The safety and efficacy of gemcitabine, S-1, and LV combination (GSL) therapy as NAC for borderline resectable (BR) and locally advanced (LA) PC was evaluated in this phase II study. Patients with pathologically proven BR or LA PC were enrolled and gemcitabine 1000 mg/m2 by 30-min infusion on day 1, S-1 40 mg/m2 orally twice daily, and LV 25 mg orally twice daily on days 1-7 every 2 weeks were provided, and evaluation by CT every 2 courses was performed. The primary end point was R0 resection rate, and the secondary endpoints were resection rate, response rate, adverse events, surgical outcomes, and survival. Twenty-four patients with PC (21 BR and 3 LA) were enrolled. Response rate and disease control rate of NAC were 17.4 and 87.0%. Grade 3 and 4 toxicities involved neutropenia (34.8%), anorexia (17.4%), and mucositis (17.4%). Serum CA19-9 level decreased by 52.2%. Resection rate was 60.9% after the median of 4 cycles and R0 resection rate was 76.5% in patients undergoing laparotomy. NAC-GSL is a feasible treatment option for BR and LAPC.

References

Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Apr 18, 2001·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·T A SohnK D Lillemoe
Apr 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
May 24, 2007·Cancer Chemotherapy and Pharmacology·Takuji OkusakaHiroshi Saito
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Oct 16, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W KoizumiY Okada
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Apr 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hideki UenoMasao Tanaka
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Aug 6, 2014·Annals of Surgical Oncology·Brian A BooneHerbert J Zeh
Aug 22, 2014·Cancer Chemotherapy and Pharmacology·Yousuke NakaiKazuhiko Koike
Dec 19, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M UenoN Boku
Oct 19, 2017·Journal of Surgical Oncology·Robert de W MarshHedy Kindler

❮ Previous
Next ❯

Citations

Jul 25, 2019·Clinical Endoscopy·Yousuke NakaiKazuhiko Koike
Jun 26, 2020·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Antolino LauraRamacciato Giovanni
Jul 2, 2021·World Journal of Gastrointestinal Surgery·Gennaro NappoAlessandro Zerbi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.